MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine"

  • 2026 International Congress

    Distinct FDG-PET metabolic patterns and connectivity alterations in dopamine transporter-deficient versus -preserved MSA-C

    Y. Zhao, H. Lin, X. Li, J. Ge, F. Liu (Shanghai, China)

    Objective: In this study, we stratified MSA-C patients by DaT-PET binding status (preserved vs deficient) and compared their 18F-FDG PET metabolic patterns and inter-regional metabolic…
  • 2026 International Congress

    Coupling of Cholinergic and Dopaminergic Terminal Loss in Progressive Supranuclear Palsy: A Multimodal [18F]FEOBV and [11C]PE2I Study

    P. Kanel, G. Carli, S. Roytman, J. Barr, R. Vangel, A. van Hout, C. Spears, P. Scott, R. Albin, N. Bohnen (Ann. Arbor, USA)

    Objective: To describe the relationships between dopaminergic and cholinergic terminal deficits in Progressive Supranuclear Palsy (PSP) relative to age-matched Normal controls (NC). Background: There is…
  • 2026 International Congress

    Dopamine and Na,K-ATPase: Mechanisms of Direct Enzyme Modulation in the Hippocampus

    G. Chkadua, E. Nozadze, L. Shioshvili, L. Tsakadze, S. Dzneladze, N. Arutinova, M. Leladze, M. Javakhishvili (Tbilisi, Georgia)

    Objective: This study aimed to investigate the direct effect of dopamine on Na,K-ATPase activity in rat hippocampal membranes and to determine whether this effect depends…
  • 2026 International Congress

    Association of DAGLB Variants with Early-Onset Parkinson’s Disease Across Populations

    Y. Mecheri, W. Kamel, E. Eltaraifee, A. Olusanya, N. Kuznetsov, GP2. Genetic Program, T. Perinan (Constantine, Algeria)

    Objective: Here, we investigated the contribution of DAGLB variants to PD across diverse ancestries using large-scale data from the Global Parkinson’s Genetics Program (GP2). Background:…
  • 2026 International Congress

    In Silico Investigation of Dopamine Receptor–Calcium Channel Coupling in Subthalamic Nucleus Neurons: Implications for Parkinson’s Disease Therapy

    A. Pradhan (Bangalore, India)

    Objective: Parkinson’s disease (PD) is characterized by disrupted dopaminergic signaling within the basal ganglia circuitry, particularly affecting the activity of subthalamic nucleus (STN) neurons [1,…
  • 2026 International Congress

    Dopaminergic Modulation Of Contextual Emotional Appraisal And Shame In Parkinson’s Disease

    S. Catalano Chiuve, D. Benis, C. Rime, M. Maradan-Gachet, J. Potheegadoo, F. Bernasconi, O. Blanke, P. Krack, V. Fleury (Geneva, Switzerland)

    Objective: To investigate the influence of dopaminergic replacement therapy (DRT) on emotional appraisal and shame-related responses in PD patients with fluctuations. Background: Shame and embarrassment…
  • 2026 International Congress

    Dopamine depletion does not mitigate striatal reward prediction error signals

    JH. Shin, JS. Kim, HK. Chung, MW. Jung (Seoul, Republic of Korea)

    Objective: To elucidate the role of dopamine in computing reward prediction error signals in the basal ganglia Background: Phasic discharges of midbrain dopamine neurons are…
  • 2026 International Congress

    R1 from 18PR04.MZ as a Proxy for Cerebral Blood Flow in Degenerative Parkinsonism: Comparison with 15O-H2O PET/CT.

    A. Damian, I. Amorin, V. Kramer, J. Higgie, I. Cordero, L. Gutierrez, E. Savio, T. Arias, O. Alonso, R. Ferrando (Montevideo, Uruguay)

    Objective: To evaluate the relationship between R1 from 18PR04.MZ and CBF assessed by 15O-H2O PET/CT in patients with parkinsonian syndromes. Background: 18PR04.MZ is an effective…
  • 2026 International Congress

    The Impact of Dopamine-Induced Impulse Control Disorders on Quality of Life in Young-Onset Parkinson’s Disease

    S. Pokhriyal, A. Gupta (Delhi, India)

    Objective: To quantify how impulse control disorders (ICDs) alter day-to-day functionality and overall quality of life (QoL) among individuals living with Young-Onset Parkinson’s Disease (YOPD),…
  • 2026 International Congress

    Complete Resolution of Troublesome Dyskinesia in People With Advanced Parkinson’s Disease Treated With Foslevodopa/Foscarbidopa: Post Hoc Analysis From a 52-Week Phase 3 Trial

    R. Hauser, A. Antonini, D. Di Luca, E. Freire-Alvarez, M. Oliveira Fernandes, M. Shah, L. Bergmann, X. Li, M. O’Meara, D. Standaert (Tampa, USA)

    Objective: To evaluate the achievement of complete elimination of troublesome dyskinesia (TSD) and associated changes in Off time, motor aspects of experiences of daily living…
  • 1
  • 2
  • 3
  • …
  • 27
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley